- An institutional investor buys $15M of Northwest Biotherapeutics (NWBO) common stock for $6.60/share, an 8% discount from yesterday's close of $7.17.
- The Stock Purchase Agreement also contains an oversubscription option to purchase an additional $17M at $7.50/share.
- The company has been under scrutiny from certain observers regarding clinical trial data for DCVax.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs